CYCN
Cyclerion Therapeutics, Inc.·Healthcare
3.13
2.344%(−0.07)
Market OpenLast Updated: — ET
52W L: $1.0352W H: $8.48
CYCN NEWS
prnewswire.com
Apr 9
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
prnewswire.com
Apr 2
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
NEW YORK, April 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) related to its merger with Korsana Biosciences, Inc. Upon the closing of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company.
businesswire.com
Apr 2
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. Upon closing of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company. Halper Sadeh encourages Cyclerion shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@h.
prnewswire.com
Apr 1
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, April 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Korsana. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
benzinga.com
Apr 1
Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing
Under the deal, the combined company is expected to operate as Korsana Biosciences and trade on the Nasdaq under the ticker symbol KRSA. The move appears to be driving enthusiasm because it gives public-market investors exposure to Korsana's lead program, KRSA-028, a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease.
seekingalpha.com
Apr 1
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
